Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31613426 | 0.83 | — | — | |
| SCHEMBL27223148 | 0.81 | — | — | |
| SCHEMBL16321457 | 0.79 | UHRF1 (0.31) | — | |
| SCHEMBL16815214 | 0.79 | PLAU (0.32) | — | |
| SCHEMBL16362377 | 0.76 | TBK1 (0.37) | — | |
| SCHEMBL20704234 | 0.76 | CA2 (0.33) | — | |
| SCHEMBL23257093 | 0.74 | — | — | |
| SCHEMBL3448876 | 0.74 | KDM4E (0.37) | — | |
| SCHEMBL13674820 | 0.74 | — | — | |
| SCHEMBL17508477 | 0.74 | MEN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229202-B | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-117229202-A | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-117229202-B | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117229202-B | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117229202-A | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117229202-A | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-110997656-B | Substituted indole compounds useful as TLR7/8/9 inhibitors | 百时美施贵宝公司 | 2023-04-14 | — | — | CN | disclosed |
| US-11447466-B2 | Substituted indole compounds useful as inhibitors of TLR7/8/9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3661926-B1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20200239437-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 | BRISTOL MYERS SQUIBB CO (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3661926-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 | Bristol-Myers Squibb Company (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019028302-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-07 | — | — | WO | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| CN-1878773-A | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | NEUROGEN CORP (US) | 2006-12-13 | — | — | CN | disclosed |
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1680424-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | Neurogen Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | AVENTIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005023806-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | NQO2 3592/4885 |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | NQO2 3592/4885 |
| US-11447466-B2 | Substituted indole compounds useful as inhibitors of TLR7/8/9 | TLR7, TLR9, TLR8 | NQO2 1419/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | NQO2 2019/4885 |
| US-20200239437-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 | TLR7, TLR9, TLR8 | NQO2 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.